Is Vandetanib on the market?

Vandetanib (Vandetanib) was approved for medical use in the United States in April 2011. Its current indication is symptomatic or progressive, unresectable or metastatic medullary thyroid carcinoma. Vandetanib is available in 100 and 300 mg tablets under the trade name Caprelsa. In 2012, the European Medicines Agency (EMA) determined that the benefits of vandetanib outweighed its risks for patients with rapidly spreading disease and symptoms, because the patients urgently needed treatment, so it was approved for marketing.

Vandertanib is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor), and RET (rearranged during transfection) tyrosine kinases. VEGFR and EGFR-dependent signaling are clinically proven pathways in cancer, including non-small cell lung cancer (NSCLC). Vandetanib has potent anti-angiogenic activity and specific potency against mutant RET tyrosine kinase, which is found in most hereditary and most idiopathic medullary thyroid carcinomas. So early data on vandetanib in medullary thyroid cancer led to orphan drug designation by U.S. and EU regulatory agencies. Clinical trials of vandetanib in advanced or metastatic medullary thyroid cancer demonstrated significant prolongation of progression-free survival.

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.